05/15/2026
As pharmaceutical innovation becomes increasingly globalized, intellectual property strategies can no longer stop at national borders.
In her recent article for Drug Discovery & Development, Partner Shelley Danek explores the realities companies face as research, development, manufacturing, and commercialization efforts increasingly span multiple jurisdictions.
The article examines why coordinated international IP strategies, early planning, and an understanding of differing patent systems are becoming essential for protecting pharmaceutical innovation in a borderless economy.
Read Shelley’s full article below⬇️
Today’s drug development programs routinely span continents: distributed research teams, multinational clinical trial networks, and complex webs of cross-border licensing, contract manufacturing, and technology transfer.